Universal Beteiligungs und Servicegesellschaft mbH Takes $1.43 Million Position in Vera Therapeutics, Inc. $VERA

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 28,323 shares of the company’s stock, valued at approximately $1,434,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of VERA. GAMMA Investing LLC increased its holdings in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares in the last quarter. Quantbot Technologies LP bought a new stake in Vera Therapeutics during the second quarter worth $51,000. Tower Research Capital LLC TRC grew its holdings in Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after buying an additional 2,757 shares in the last quarter. AlphaQuest LLC grew its holdings in Vera Therapeutics by 414.2% during the third quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock worth $152,000 after buying an additional 4,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Vera Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock worth $157,000 after buying an additional 639 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on VERA shares. HC Wainwright upped their price target on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.45.

Vera Therapeutics Trading Down 1.2%

Shares of Vera Therapeutics stock opened at $35.20 on Friday. The stock has a fifty day simple moving average of $40.34 and a 200 day simple moving average of $40.18. Vera Therapeutics, Inc. has a 12-month low of $18.76 and a 12-month high of $56.05. The company has a market capitalization of $2.51 billion, a P/E ratio of -7.55 and a beta of 0.96. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same quarter in the previous year, the company posted ($0.72) earnings per share. On average, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -5.33 earnings per share for the current fiscal year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $207,759.02. Following the completion of the transaction, the chief financial officer owned 114,181 shares in the company, valued at $4,793,318.38. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William D. Turner sold 2,187 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the transaction, the insider owned 45,313 shares of the company’s stock, valued at $1,902,239.74. This trade represents a 4.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 56,441 shares of company stock worth $2,416,902. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.